Bhavana Balakrishnan
Good afternoon, everybody. Thank you so much for joining us on day 3 of the J.P. Morgan Healthcare Conference. My name is Bhavana Balakrishnan, and I’m an associate from the health care investment banking team. We are here today for the presentation of Disc Medicine, and we’re joined by John Quisel, Chief Executive Officer. And I’ll turn it over to you, John.
John Quisel
CEO, President & Director
Great. Thank you. All right. Great to be here. Thanks, everyone, for taking sometime today. I guess Wednesday afternoon, we’ve reached maybe the exhaustion stage of the conference. But thanks to the J.P. Morgan team for providing a speaking slide for us here.
Okay. So it’s — we’re about the — 3 years public listed here at Disc. It’s been an exciting run, highly productive. We look forward to next year being a really exciting year. We’re on the cusp of approval of our lead program, and then we have a whole pipeline behind that progressing well. So we’ll walk through all that today.
First, a few disclaimers. We’ll be making forward-looking statements. Everything should be taken in context with what we filed on our website and with the SEC. And 3 clinical programs, we’ll be talking about, DISC — sorry, bitopertin, DISC-0974 and DISC-3405. These are investigational agents, and they’re not approved as therapies anywhere in the world.
So a quick rundown. I’ll — for those less familiar with the story, I’ll give a brief intro of who we are here at Disc. And then we’ll run through our lead program, some of the background, the progress towards approval and then some launch
Credit: Source link
